Pharmacological antagonism of HTR2B reduces ERK and STAT3 activation and prevents renal fibrosis during the development of Adenine-Induced CKD in rats
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.118482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Kai W McAlister und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, University of Arizona, Tucson, AZ, USA; Southwest Environmental Health Science Center, University of Arizona…. Hauptthemen laut MEDLINE: Adenine, STAT3 Transcription Factor, Renal Insufficiency, Chronic, Serotonin 5-HT2 Receptor Antagonists. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIEHS NIH HHS, BLRD VA.
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a debilitating condition affecting roughly 1 in 7 people in the United States. CKD is characterized by loss of renal function due to nephron loss and fibrosis. MARY1 is a novel 5-hydroxytryptamine 2B receptor (HTR2B) antagonist that stimulates mitochondrial biogenesis and augments recovery after ischemia/reperfusion-induced acute kidney injury (AKI) in vivo. We evaluated the potential of MARY1 to prevent CKD development in an adenine-induced rat model. Rats were given a normal diet or a diet supplemented with 0.2% adenine for 4 weeks to induce CKD. Adenine-fed rats were simultaneously administered either MARY1 (0.15 mg/kg, IP) or vehicle daily throughout the 4 weeks. Adenine diet resulted in renal cortical fibrosis and upregulation of two kidney damage markers: kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL), consistent with CKD development. MARY1 mitigated the induction of KIM-1 and NGAL by 52% and 68%, respectively. Nicotinamide adenine dinucleotide (NAD + ) was reduced by 69% in vehicle-treated adenine-exposed rats, which was prevented by MARY1. Adenine increased activation of extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3), resulting in increased expression of the pro-inflammatory transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). MARY1 reduced activation of ERK and STAT3, and mitigated NF-κB upregulation by 64%. MARY1 also attenuated adenine-induced fibrosis in the renal cortex by 43%. These findings support HTR2B antagonism as a novel strategy for preventing CKD-associated mitochondrial dysfunction, renal inflammation, and fibrosis during disease development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, University of Arizona, Tucson, AZ, USA; Southwest Environmental Health Science Center, University of Arizona, Tucson, AZ, USA.
- Department of Pharmacology & Toxicology, University of Arizona, Tucson, AZ, USA; Southern Arizona VA Health Care System, Tucson, AZ, USA.
- Department of Pharmacology & Toxicology, University of Arizona, Tucson, AZ, USA.
- Department of Pharmacology & Toxicology, University of Arizona, Tucson, AZ, USA; Southwest Environmental Health Science Center, University of Arizona, Tucson, AZ, USA; Southern Arizona VA Health Care System, Tucson, AZ,…
Förderung
- NCI NIH HHS
- NIEHS NIH HHS
- BLRD VA
- National Institutes of Health National Cancer Institute
- National Institutes of Health
- US Department of Veterans Affairs
- National Institute of Environmental Health Sciences
Zitieren
APA
McAlister, K. W., Scholpa, N. E., Janda, J., & Schnellmann, R. G. (2026). Pharmacological antagonism of HTR2B reduces ERK and STAT3 activation and prevents renal fibrosis during the development of Adenine-Induced CKD in rats. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118482
Vancouver
McAlister KW, Scholpa NE, Janda J, Schnellmann RG. Pharmacological antagonism of HTR2B reduces ERK and STAT3 activation and prevents renal fibrosis during the development of Adenine-Induced CKD in rats. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118482
BibTeX
@article{McAlister2026,
author = {McAlister, Kai W and Scholpa, Natalie E and Janda, Jaroslav and Schnellmann, Rick G},
title = {Pharmacological antagonism of HTR2B reduces ERK and STAT3 activation and prevents renal fibrosis during the development of Adenine-Induced CKD in rats},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.118482}
}
EUVIMED